Cardiac dysfunction in the trastuzumab clinical trials experience.
暂无分享,去创建一个
C. Hudis | S. Shak | M. Murphy | S. Stewart | V. Paton | A. Seidman | Steven Shak | Deborah Keefe | Maureen Murphy | Stanford J Stewart | Clifford Hudis | D. Keefe | Andrew Seidman | Mary Kathryn Pierri | Virginia Paton | Mark Ashby | M. Ashby | M. K. Pierri
[1] D A Berry,et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.
[2] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[3] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[4] J. Chapelle. Cardiac Troponin I and Troponin T: Recent Players in the Field of Myocardial Markers , 1999, Clinical chemistry and laboratory medicine.
[5] J. Mason,et al. Anthracycline cardiomyopathy monitored by morphologic changes. , 1978, Cancer treatment reports.
[6] P. Poole‐Wilson,et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.
[7] P. Ravdin,et al. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. , 1995, Gene.
[8] K S Panageas,et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Kuo-Fen Lee,et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.
[10] D. Cox. Regression Models and Life-Tables , 1972 .
[11] J. Ross,et al. Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.
[12] K. Chien. Genomic circuits and the integrative biology of cardiac diseases , 2000, Nature.
[13] H. Gibbs,et al. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? , 1999, Seminars in oncology.
[14] P. Singal,et al. Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.
[15] K. Chien,et al. Stress Pathways and Heart Failure , 1999, Cell.
[16] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.